The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Noonan syndrome and clinically related disorders
Open accessAbstract
Noonan syndrome is a relatively common, clinically variable developmental disorder. Cardinal features include postnatally reduced growth, distinctive facial dysmorphism, congenital heart defects and hypertrophic cardiomyopathy, variable cognitive deficit and skeletal, ectodermal and hematologic anomalies. Noonan syndrome is transmitted as an autosomal dominant trait, and is genetically heterogeneous. So far, heterozygous mutations in nine genes (PTPN11, SOS1, KRAS, NRAS, RAF1, BRAF, SHOC2, MEK1 and CBL) have been documented to underlie this disorder or clinically related phenotypes. Based on these recent discoveries, the diagnosis can now be confirmed molecularly in approximately 75% of affected individuals. Affected genes encode for proteins participating in the RAS-mitogen-activated protein kinases (MAPK) signal transduction pathway, which is implicated in several developmental processes controlling morphology determination, organogenesis, synaptic plasticity and growth. Here, we provide an overview of clinical aspects of this disorder and closely related conditions, the molecular mechanisms underlying pathogenesis, and major genotype-phenotype correlations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lodish, H. F. (1986) · Cited by 5,650
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Self-citationNeurofibromatosis: Conference Statement
(1988) · Archives of Neurology · doi:10.1001/archneur.1988.00520290115023 · Cited by 1,547
Birth Defects: Original Article Series.
(1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-157_8 · Cited by 1,387
The Ras superfamily at a glance
Wennerberg, K., Rossman, K. L., & Der, C. J. (2005) · Journal of Cell Science · doi:10.1242/jcs.01660 · Cited by 1,352
Brown, A. S., Brummel‐Smith, K., Burgess, L., D'Agostino, R. B., Goldschmidt, J. W., Halter, J. B., Hazzard, W. R., Jahnigen, D. W., Phelps, C., Raskind, M., et al. (1988) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1988.tb02362.x · Cited by 1,331
The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling
Neel, B. G., Gu, H., & Pao, L. (2003) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(03)00091-4 · Cited by 1,249 · cited 1×
“The PTPN11 gene (OMIM 176876) encodes SHP2, a cytoplasmic protein tyrosine phosphatase that positively modulate RAS signaling [72].”
BackgroundNeurofibromatosis. Conference statement, National Institute of Health development conference
Stumpf, D. A. (1988) · JAMA Neurology · Cited by 1,236
The RAF proteins take centre stage
Wellbrock, C., Karasarides, M., & Marais, R. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1498 · Cited by 1,228
Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003) · Nature Genetics · doi:10.1038/ng1156 · Cited by 1,033
Self-citation
Cited by
2023 ESC guidelines for the management of cardiomyopathies
Arbelo, E., Protonotarios, A., Gimeno, J. R., Arbustini, E., Barriales-Villa, R., Basso, C., Bezzina, C. R., Biagini, E., Blom, N. A., de Boer, R. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad194 · Cited by 2,844
Pierpont, M. E., Brueckner, M., Chung, W. K., Garg, V., Lacro, R. V., McGuire, A. L., Mital, S., Priest, J. R., Pu, W. T., Roberts, A., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000606 · Cited by 654
Self-citationMolecular genetic testing and the future of clinical genomics
Katsanis, S. H., & Katsanis, N. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3493 · Cited by 425
The neural crest in cardiac congenital anomalies
Keyte, A., & Hutson, M. R. (2012) · Differentiation · doi:10.1016/j.diff.2012.04.005 · Cited by 259
SHP2 sails from physiology to pathology
Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.08.005 · Cited by 232
K-Ras V14I recapitulates Noonan syndrome in mice
Hernández-Porras, I., Fabbiano, S., Schuhmacher, A. J., Aicher, A., Cañamero, M., Cámara, J. A., Cussó, L., Desco, M., Heeschen, C., Mulero, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418126111 · Cited by 96
Vissers, L. E., Bonetti, M., Paardekooper Overman, J., Nillesen, W. M., Frints, S. G. M., de Ligt, J., Zampino, G., Justino, A., Machado, J. C., Schepens, M., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.115 · Cited by 75
“[4,6] To date, all mutations causing NS result in enhanced activation of signal transducers belonging to the RAS-mitogen activated protein kinase (MAPK) pathway.[7]”
BackgroundSelf-citationA review of craniofacial and dental findings of the RASopathies
Cao, H., Alrejaye, N., Klein, O. D., Goodwin, A. F., & Oberoi, S. (2017) · Orthodontics & Craniofacial Research · doi:10.1111/ocr.12144 · Cited by 63
Maher, G. J., McGowan, S. J., Giannoulatou, E., Verrill, C., Goriely, A., & Wilkie, A. O. M. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521325113 · Cited by 59
Filges, I., Sparagana, S., Sargent, M., Selby, K., Schlade‐Bartusiak, K., Lueder, G. T., Robichaux‐Viehoever, A., Schlaggar, B. L., Shimony, J. S., & Shinawi, M. (2014) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36605 · Cited by 30
“Neurofibromin, which is deficient in NF1 and activates RAS specific GTPase, is also implicated in this pathway [Tartaglia et al., 2011].”
BackgroundMozzi, A., Forni, D., Cagliani, R., Pozzoli, U., Clerici, M., & Sironi, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06440-4 · Cited by 19
Using deep learning and electronic health records to detect Noonan syndrome in pediatric patients
Yang, Z., Shikany, A., Ni, Y., Zhang, G., Weaver, K. N., & Chen, J. (2022) · Genetics in Medicine · doi:10.1016/j.gim.2022.08.002 · Cited by 20
K‐RasV14I‐induced Noonan syndrome predisposes to tumour development in mice
Hernández‐Porras, I., Schuhmacher, A. J., Garcia‐Medina, R., Jiménez, B., Cañamero, M., de Martino, A., & Guerra, C. (2016) · The Journal of Pathology · doi:10.1002/path.4719 · Cited by 16
MAPK activation in mature cataract associated with Noonan syndrome
Hashida, N., Ping, X., & Nishida, K. (2013) · BMC Ophthalmology · doi:10.1186/1471-2415-13-70 · Cited by 14
“Noonan-like syndromes comprising Costello syndrome (CS; OMIM 218040), cardiofaciocutaneous syndrome (CFCS, OMIM 115150), neurofibromatosis type 1 (NF1; OMIM 162200), and Legius syndrome (NFLS, OMIM 611431) are disorders clinically related to NS and also harbor mutations in HRAS, KRAS, NF1, BRAF, SPRED1, MEK1, and MEK2…”
Background
Metadata
- Authors
- Tartaglia, M., Gelb, B. D., & Zenker, M.
- Venue
- Best Practice & Research Clinical Endocrinology & Metabolism
- Publisher
- Elsevier BV
- Published
- 2011-02
- Volume
- 25
- Issue
- 1
- Pages
- 161-179
- ISSN
- 1521-690X (ISSN-L)
- OpenAlex
- W2081635903
- Cited by
- 414
- References
- 114
- FWCI
- 10.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.